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Enzyme replacement therapy (ERT)Fabry disease is treated by two-weekly infusions with α-galactosidase A, which is deﬁcient in this X-linked
globotriaosylceramide (Gb3) storage disorder. Elevatedplasmaglobotriaosylsphingosine (lysoGb3) is a hallmark
of classical Fabry disease. We investigated effects of enzyme replacement therapy (ERT) on plasma levels of
lysoGb3 andGb3 in patientswith classical Fabry disease treatedwith agalsidase alfa at 0.2 mg/kg, agalsidase beta
at 0.2 mg/kg or at 1.0 mg/kg bodyweight. Each treatment regimen led toprominent reductions of plasma lysoGb3
in Fabry males within 3 months (P=0.0313), followed by relative stability later on. Many males developed
antibodies against α-galactosidase A, particularly those treated with agalsidase beta. Patients with antibodies
tended towards smaller correction in plasma lysoGb3 concentration, whereas treatment with high dose
agalsidase beta allowed a reduction comparable to patients without antibodies. Pre-treatment plasma lysoGb3
concentrations of Fabry females were relatively low. In all females and with each treatment regimen, ERT gave
reductionor stabilisation of plasma lysoGb3.Our investigation revealed that ERTof Fabry patients reducesplasma
lysoGb3, regardless of the recombinant enzyme used. This ﬁnding shows that ERT can correct a characteristic
biochemical abnormality in Fabry patients.ase; ERT, enzyme replacement
ide; GLA gene,α-galactosidase
globotriaosylsphingosine; OPA,
Amsterdam, The Netherlands.
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The lysosomal storage disorder Fabry disease (OMIM 301500)
results from deﬁcient activity of the lysosomal hydrolase α-galactosi-
dase A (EC 3.2.1.22) [1,2]. Since the α-galactosidase A (GLA) gene is
located on Xq22.1, hemizygous males suffer from Fabry disease.
However, many female heterozygotes also display symptoms despite
considerable amounts of circulating residual enzyme that varies due to
random X-inactivation [3,4]. In both males and females different
phenotypic manifestations of Fabry disease occur [2]. The classical
manifestations in males involve angiokeratoma, anhidrosis and acro-
paresthesias at puberty, followed by renal insufﬁciency, left ventricular
hypertrophy (LVH) and cerebrovascular disease in the fourth or ﬁfthdecade of life. In females the disease manifestations are usually, but not
always, attenuated. A complete lack or severely reducedα-GalA activity
results in classical manifestations of Fabry disease. During the past
decades α-Gal A deﬁcient patients with relatively few and isolated
symptoms, such as LVH or renal failure at later stages in life, have been
described [2,5,6]. These patients are generally referred to as atypical
Fabry patients, to distinguish them from those with multi-organ
symptoms at a young age. Relatively high residual α-Gal A activity is
often noted in these atypical cases [2]. The precise causes for the
remarkable heterogeneous manifestations of Fabry disease are still
poorly understood [5,7–9]. The nature of mutations in the GLA gene and
the corresponding degree of residual α-Gal A activity, undoubtedly
inﬂuence diseasemanifestations [10–12]. There is growing evidence for
other modiﬁers beyond the GLA gene. For example, a modulating role
maybe envisioned forα-galactosidaseB, anotherα-galactosidase arisen
by gene duplication with low activity towards the lipid substrate of
α-Gal A [13,14]. In addition, polymorphisms c.174GNC of interleukin-6,
c.894GNT of endothelial nitric oxide synthase (eNOS), factor V
c.1691GNA mutation (factor V Leiden), and the c.13ANG and c.79GbA
of protein Z are all signiﬁcantly associatedwith the presence of cerebral
white matter lesions on brain MRI [15]. Two polymorphisms in the
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hypertrophic cardiomyopathy as measured by left posterior wall
thickness of the heart [16].
Deﬁciency ofα-GalA results in accumulation of its glycosphingolipid
substrates in lysosomes of endothelial, perithelial, and smooth muscle
cells of the vascular system, as well as renal epithelial cells, myocardial
cells, and cells of the autonomic nervous system [17]. The accumulating
glycosphingolipids contain terminal α-galactosyl moieties, such as
globotriaosylceramide (Gb3; also named ceramidetrihexoside); gala-
biosylceramide (Gb2); and, to a lesser extent, blood group B, B1, and P1
antigens [2,18]. The prominent lysosomal storage of Gb3 in cells of the
arterial wall is generally thought to cause a systemic vasculopathywith
progressive renal insufﬁciency, cardiac involvement and CNS pathology
in Fabry patients [2,9,19]. Symptomatic Fabry hemizygotes, but not
most heterozygotes, show increased plasma Gb3 levels [2,4]. Mass
spectrometry-based andHPLC-based procedures have becomeavailable
allowing accurate quantiﬁcation of the globoside [20–24]. Plasma Gb3
has been found to poorly reﬂect Fabry disease manifestations and
therapeutic outcome [4,25–27]. Recently, another striking lipid abnor-
mality has been noted in patients with classical Fabry disease
manifestations [28]. Globotriaosylsphingosine is deacylated globotriao-
sylceramide (designated as lysoGb3). The relative increase in theplasma
lysoGb3 exceeds that of Gb3 by more than an order of magnitude. High
nanomolar lysoGb3 concentrations occur in plasma samples from
symptomatic Fabry males with classical disease manifestations. Also in
symptomatic Fabry females, clearly increased levels of lysoGb3 occur
whilst concomitantly Gb3 concentrations are in the normal range [28].
Two different recombinant α-Gal A preparations are in use for the
treatment of Fabry disease [29,30]. One enzyme is produced using
Chinese hamster ovary cells with classic recombinant technology
(agalsidase beta, Fabrazyme) and the other enzyme is produced using
cultured human skin ﬁbroblastswith an activated promoter of theα-gal
A gene (agalsidase alfa, Replagal). Both recombinant enzymes are
comparable in properties and differ only slightly in glycan composition
[31]. The two enzyme preparations have independently been examined
in clinical investigations and are both registered in Europe for the
treatment of Fabry patients. Although both enzyme replacement
therapies (ERTs) were found to result in the desired clearance of Gb3
from theendothelium, the clinical effects are not as robust as anticipated
based on the impact of ERT in type 1 Gaucher disease [32]. In some
patients stabilization of renal function and improvement in cardiac
hypertrophy occurs upon therapy, but a considerable number experi-
ence progressive complications [33]. From a recent analysis of the Fabry
Outcome Survey observational database, it was concluded by compar-
ison with historical natural history data for patients who were not
treated with ERT, that long-term treatmentwith agalsidase alfa leads to
substantial and sustained clinical beneﬁts [34]. However, discerning the
speciﬁc effect of ERT from that of other interventions, for example the
use of renin–angiotensin inhibitors, remains a challenge [35]. It has been
documented that a large portion of Fabry hemizygotes develops
antibodies against the recombinant enzymes during ERT [36–38]. In
addition, it has been hypothesized that the formation of antibodies
possibly affects outcome [39,40].
Since monitoring of efﬁcacy of ERT is hampered by the heteroge-
neous manifestations of Fabry disease as well as the irreversible nature
of many symptoms, we investigated the impact of therapy on plasma
lysoGb3 levels in patients with classical Fabry disease manifestations.
Plasma lysoGb3 can be accurately quantiﬁed and offers an objective
parameter to assess whether the underlying biochemical deﬁciency in
Fabry patients is corrected by therapy. In a previous study, we
investigated outcomes of Gb3 levels in relation to different ERTs [38].
Wehere report the outcomeof the investigation inwhichplasmaGb3 as
well as lysoGb3 levels were monitored in patients receiving either
agalsidase alfa (0.2 mg) or agalsidase beta (0.2 or 1.0 mg) per kg
bodyweight every 2 weeks. The impact of formation of neutralizing
anti-(α-Gal A) antibodies on plasma lipid corrections is also described.2. Materials and Methods
2.1. Classical Fabry disease patients and controls
Control subjects for Gb3 analysis consisted of 10males and15 females.
Plasma lysoGb3 levels were measured in 9 male and 9 female healthy
volunteers (age range 5–77 years). Forty-three Fabry patients (22 males
and 21 females; age range 18–71 years) from the Academic Medical
Center (AMC) and from the UniversitätsklinikumWürzburg (UKW) who
presented with classical Fabry disease and received a minimum of
12 months of ERT were eligible for this study. This is a subset of patients
described in an earlier study [38] excluding patients with an atypical
variant of disease and with incomplete sample collection. All patients
were treatmentnaïveprior toenrolment. Classical Fabrydisease isdeﬁned
by the presence of characteristic symptoms and elevated plasma lysoGb3
and/or Gb3 in hemizygotes, and in case of heterozygotes, having a
mutation known to be associated with a classical phenotype (through
literature or a male family member with classical symptoms). Patients
received three different ERT treatments: infusions every two weeks with
agalsidase alfa at 0.2 mg/kg (n=14; 7 males and 7 females), agalsidase
beta at 0.2 mg/kg (n=11; 6 males and 5 females), or agalsidase beta at
1.0 mg/kg (n=18; 9 males and 9 females). All patients had been
diagnosed by means of a reduced α-Gal A activity in leukocytes (males)
and/or a mutation in the α-Gal A gene (females) [33]. None of the
investigated male Fabry patients showed a residual enzyme activity
exceeding 5% of the normal mean. Stored blood samples from Fabry
disease patients were analyzed. Informed consent and approval of the
institutional review board had been obtained as part of a previous
study [38].
2.2. Antibodies
Serum samples were evaluated for the presence of anti-(α-Gal A)
antibodies as previously described [36]. To assess neutralizing activity,
different volumes of serum (0.1–10 μl of serum, corresponding to a
dilution of 1/150–1/1.5) were incubated with a standard amount of
recombinant α-galactosidase A (agalsidase beta, 2.1 ng). Enzyme activity
was determined after 10minutes of incubation at room temperature. The
serum dilution that resulted in 50% reduction of the enzyme activity was
recorded (IC50). Assuming a linear relationship, the amount of enzyme
that would be inhibited by 1 μl of serum was calculated.
2.3. Plasma Gb3 and lysoGb3
Plasma Gb3 and lysoGb3 were determined at t=0, t=3 and
t=12months of ERT. If available, lipid concentrations were also
measured in plasma specimens obtained after 6 and 9 months of
treatment. Quantitation of Gb3 in plasma samples was performed as
described previously [24]. Quantitativemeasurements of plasma lysoGb3
were performed as described with minor modiﬁcations [28,41]. Brieﬂy,
100 μl of plasma was extracted with 600 μl of chloroform/methanol 1/2
(vol/vol). The extractwas centrifuged for 10 min at 14,000g and the pellet
was discarded. To the supernatant, 500 μl chloroform/MQ-H2O 1/1.5
(vol/vol) was added, mixed, and centrifuged for 2 min at 14,000g to
separate the phases. The upper phase was collected, and the lower
chloroformphasewas re-extractedwith 500 μl ofmethanol/MQ-H2O 1/1
(vol/vol) toquantitatively extract all lysoGb3. The combinedupperphases
weredriedundernitrogenﬂow, takenup in500 μlMQ-H2O, andextracted
twice with 500 μl of water-saturated 1-butanol. LysoGb3 was recovered
from the butanol phase with an overall recovery of N90%. The butanol
phase was dried, dissolved in 120 μl (hemizygotes) or 90 μl (hetero-
zygotes) of freshly prepared 0.1 M NaOH in methanol and incubated at
37 °C for 1 h. Of this solution, 50 μl was derivatized with 25 μl of
o-phtaldialdehyde (OPA) reagent (5 mg of OPA, 100 μl of ethanol, 5 μl of
2-mercaptoethanol, and 10 ml of 3% boric acid, pH 9.0). The OPA-
derivatized lysoGb3 was separated by HPLC and quantiﬁed by
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Fig. 1. Plasma levels of lysoGb3 and Gb3 in controls and Fabry patients prior to therapy. (A) Plasma lysoGb3 levels in male control subjects (n=9) and male Fabry patients (n=22).
(B) Plasma Gb3 levels inmale control subjects (n=10) andmale Fabry patients (n=22). (C) Plasma lysoGb3 levels in female control subjects (n=9) and female Fabry patients (n=21).
(D) Plasma Gb3 levels in female control subjects (n=15) and female Fabry patients (n=21). Lipid levels were determined as described in Materials and methods. The horizontal line
represents the median value in each group. P-values (two-tailed Mann–Whitney rank sum test) are indicated when subgroups were statistically different. NS, not signiﬁcant.
1 Plasma lysoGb3 and Gb3 concentrations of male patients were not signiﬁcantly
different at t=0 in any of the 4 groups described in Fig. 3 (P=0.2505 and P=0.2088,
respectively).
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were extracted in duplicate. Quantiﬁcation was performed by addition of
lysoGb3 (Sigma-Aldrich) to normal plasma at concentrations ranging
from 0 to 1 mM. The limit of detection of plasma lysoGb3 is 3 nM.
2.4. Statistical methods
Results are given as median and range. Differences in lipid levels
between groupswere assessed by theMann–WhitneyU-test (2 groups)
and the Kruskal–Wallis test (N2 groups). To compare lipid levels
betweenpatients before and after therapy, datawere analyzedusing the
Wilcoxon matched pairs test (2 time points). To compare lipid levels
between patients before and after one year of therapy, data were
analyzed using repeatedmeasures analysis of variance (N2 timepoints).
For this analysis lipid data of individuals were expressed as percentage
of t=0 (pre-treatment). Correlations were tested by the rank
correlation test (Spearman coefﬁcient, ρ). Results were considered to
be statistically signiﬁcant when two-tailed P-values were b0.05.
3. Results
3.1. Pre-treatment plasma concentrations of lysoGb3 and Gb3
Patients with classical manifestations of Fabry disease receiving ERT
for a minimum period of one year were analyzed on plasma
concentrations of lysoGb3 and Gb3. All patients (22 males and 21
females) showed increased plasma lysoGb3 levels prior to ERT (Fig. 1).
One female patient formed an exception, having a very low lysoGb3
level. All males showed elevated plasma Gb3, but only in 3 females the
concentration of Gb3 was above the normal range (Fig. 1).
3.2. Effect of different ERT regimens on plasma lipids in hemizygotes
Fig. 2 shows the effect of ERT on lysoGb3 and Gb3 levels for
hemizygotes. Plasma lysoGb3 and Gb3 concentrations of male patients
were not signiﬁcantly different at t=0 in any of the 3 treatment groups(P=0.8175 and P=0.1223, respectively). Already after 3 months of
ERT, independent of the treatment regimen, a signiﬁcant reduction
(P=0.0313) in plasma lysoGb3 concentration was reached. Thereafter
lysoGb3 levels did not decrease further up to 12 months of treatment
(P-values for each treatment regimen N0.05; see also Fig. 2, Table 1).
Reductions in plasma Gb3 by ERT were noted within 3 months of ERT
(P-values for each treatment regimen b0.01). Comparison of the
changes in plasma lysoGb3 (or Gb3) concentration induced by the 3
different treatments revealed no clear difference (see Fig. 2). The use of
repeated measures analysis of variance revealed that the reduction in
plasma lysoGb3 was signiﬁcantly larger for patients treated with
agalsidase beta at 1.0 mg/kg compared with patients treated with
agalsidase alfa (P=0.003) and beta (P=0.046) at a dose of 0.2 mg/kg.
3.3. Formation of anti-(α-Gal A) antibodies and impact on plasma lipid
reduction
We examined the inﬂuence of the treatment regimens on formation
of neutralizing antibodies. Table 2 shows that 16 of the 22 hemizygotes
had detectable antibodies. The lowest percentage of antibody formation
(43%) was noted for patients receiving agalsidase alfa. The dose of
agalsidase beta did not seem to strongly determine the chance on
antibody formation in hemizygotes (0.2 mg/kg: 83%, 1.0 mg/kg: 89%).
None of the female patients developed anti-(α-Gal A) antibodies.
The impact of the presence of neutralizing antibodies on ERT-induced
reductions in plasma lysoGb3 and Gb3 was examined. Plasma lysoGb3
and Gb3 levels at t=0 were comparable in hemizygotes, whether
developing antibodies during ERT or not (P=0.0972 and P=0.3568,
respectively). Plasma lysoGb3 concentrations tended to be higher in
hemizygoteswith antibodieswhen treated for 12 monthswith agalsidase
alfa or beta at a dose of 0.2 mg/kg, compared with hemizygotes without
antibodies1 (Fig. 3). This was not the case for patients treated for
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Fig. 2. Effect of different treatment regimens on plasma lipid levels in male Fabry
patients. (A) Plasma lysoGb3 levels in male Fabry patients prior to therapy and after 3,
6, 9 and 12 months of therapy. (B) Plasma Gb3 levels in male Fabry patients prior to
therapy and after 3, 6, 9 and 12 months of therapy. R0.2, treatment with agalsidase alfa
at 0.2 mg/kg; F0.2, treatment with agalsidase beta at 0.2 mg/kg; F1.0, treatment with
agalsidase beta at 1.0 mg/kg. Data are presented as mean (and sd) values at the
indicated time points for each group.
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picture emerges when analyzing lipid data of individuals expressed as
percentage of t=0 (pre-treatment) using repeated measures analysis of
variance: the reduction in plasma lysoGb3 is signiﬁcantly less for patients
with antibodies receiving a dose of 0.2 mg/kg agalsidase alfa (P=0.008)
compared to those without antibodies. The effect was less for patients
with antibodies receiving a dose of 0.2 mg/kg agalsidase beta (P=0.192).
Of note, this analysis indicated that the plasma lysoGb3 reduction in
patients receiving a dose of 0.2 mg/kg agalsidase alfa was just not
signiﬁcantly different from that in patients receiving a dose of 0.2 mg/kgTable 1
Effect of different treatment regimens on plasma levels of lysoGb3 and Gb3 in male Fabry pa
treatment with agalsidase alfa at 0.2 mg/kg; F0.2, treatment with agalsidase beta at 0.2 mg/k
normal values for Gb3 b3.18 μM.
Males LysoGb3 (nM)
t=0 t=3
Median Range n Median
Total 192 (102–397) 22 65
R0.2 220 (148–250) 7 86
F0.2 192 (102–263) 6 87
F1.0 189 (134–397) 9 52
Males Gb3 (μM)
t=0 t=3
Median Range n Median
Total 6.52 (3.31–9.10) 22 3.22
R0.2 7.03 (5.95–8.80) 7 4.31
F0.2 4.91 (3.31–9.10) 6 3.08
F1.0 6.56 (3.97–8.74) 9 2.91agalsidase beta (P=0.082). The lysoGb3 reduction in patients receiving a
dose of 1.0 mg/kg agalsidase beta was comparable to that in patients
without antibodies (P=0.497).
3.4. Effect of different ERT regimens on plasma lipids in heterozygotes
Finally, we investigated the response of plasma lipid concentrations
in heterozygotes to different treatment regimens. Plasma lysoGb3
and Gb3 concentrations of female patients were not signiﬁcantly
different at t=0 in any of the 3 treatment groups (P=0.5398 and
P=0.4138, respectively; see also Table 3). During ERT plasma Gb3
concentrations hardly changed, which is not surprising given the fact
that these are mostly within the normal range (upper limit of normal
range 3.18 μM). In female patients, plasma lysoGb3 concentrations at
t=0 were rather low, compared with males. The range of plasma
lysoGb3 concentrationswas large in some of the treatment groups. One
female patient showed lysoGb3 levels below the detection limit at start
of ERT whereas another heterozygote, also receiving 1.0 mg/kg
agalsidase beta, showed a relatively high lysoGb3 (143 nM). Thus, a
direct comparison of the effect of different treatments on plasma
lysoGb3 in female patients is difﬁcult given the heterogeneity among
the studied patients; however most patients (n=17) showed a
reduction with ERT. A minority (n=4) showed stabilization at low
level with ERT. None of the female patients showed an increase in
plasma lysoGb3 with ERT.
4. Discussion
ERT of Fabry disease is extremely costly and demonstration of its
clinical efﬁcacy is difﬁcult. Reductions in the storage lipid Gb3 in skin,
kidney and cardiac biopsies have been documented earlier [29],
substantiating the ability of recombinant α-Gal A preparations to
effectively supplement cells of Fabry patientswith degradative capacity.
Unfortunately, plasma Gb3 concentration has not been found to be a
useful surrogate marker and the use of sequential plasma Gb3
measurements for monitoring efﬁcacy of ERT has not been recom-
mended [26,27]. Recently it has become clear that plasma lysoGb3
elevation is a characteristic feature of patients with classical manifesta-
tions of Fabry disease [28]. The increase in the plasma concentration of
this lipid is most striking in hemizygotes. The relative extent of the
increase in plasma concentration of lysoGb3 in Fabry patients is far
larger than that of Gb3. The aim of our investigation was to establish
whether plasma lysoGb3 concentrations of Fabry patients are changed
by ERT, and may have potential as a surrogate marker to monitor
therapeutic intervention. For this purpose, patients with classicaltients. The data reﬂect absolute numbers (median and range) and sample size (n). R0.2,
g; F1.0, treatment with agalsidase beta at 1.0 mg/kg. Normal values for lysoGb3 b3 nM,
t=12
Range n Median Range n
(20–136) 18 61 (16–149) 22
(46–136) 6 118 (52–149) 7
(20–120) 6 96 (16–131) 6
(33–76) 6 55 (23–113) 9
t=12
Range n Median Range n
(1.72–5.50) 18 3.17 (1.34–6.42) 22
(2.74–5.29) 6 3.74 (3.07–6.42) 7
(2.22–5.50) 6 3.38 (1.85–3.93) 6
(1.72–3.57) 6 2.77 (1.34–3.37) 9
Table 2
Antibody formation in male Fabry patients treated with different treatment regimens.
The data reﬂect absolute and relative (%) numbers. R0.2, treatment with agalsidase alfa
at 0.2 mg/kg; F0.2, treatment with agalsidase beta at 0.2 mg/kg; F1.0, treatment with
agalsidase beta at 1.0 mg/kg. AB+, patients with neutralizing antibodies; AB−, patients
without neutralizing antibodies.
Males Total AB+ AB− % AB+
Total 22 16 6 73
R0.2 7 3 4 43
F0.2 6 5 1 83
F1.0 9 8 1 89
74 M.J. van Breemen et al. / Biochimica et Biophysica Acta 1812 (2011) 70–76manifestations of Fabry disease were examined that were treated by
two weekly intravenous administration of agalsidase alfa at 0.2 mg/kg,
agalsidase beta at 0.2 mg/kg, or agalsidase beta at 1.0 mg/kg.
In all investigated male patients plasma lysoGb3 was high prior
to ERT (102–397 nM; control subjects: b3 nM). The 3 different
treatment regimens all resulted in marked reductions in lysoGb3
within 3 months, after which the levels tended to stabilize. No clear
differences were noted between the different treatments. Examina-
tion of the occurrence of anti-(α-Gal A) antibodies, determined by an
in vitro neutralizing assay, revealed a high incidence, particularly
among patients receiving agalsidase beta. Treatment with a high dose
agalsidase beta led to a similar reduction in plasma lysoGb3 as
observed in patients without antibodies. This suggests that a dose
increase can compensate for reduced efﬁcacy of recombinant α-Gal A
in individuals with anti-(α-Gal A) antibodies. Negative effects of
antibodies on ERT-induced reductions in urinary Gb3 were reported
earlier, which also could be compensated by the use of high dose
enzyme infusion [36–38].0 3 6 9 12
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Fig. 3. Effect of different treatment regimens on plasma lipid levels in male Fabry
patients with and without anti-(α-Gal A) antibodies. (A) Plasma lysoGb3 levels in male
Fabry patients with (AB+) and without (AB−) anti-(α-Gal A) antibodies prior to
therapy and after 3, 6, 9 and 12 months of therapy. (B) Plasma Gb3 levels in male Fabry
patients with and without anti-(α-Gal A) antibodies prior to therapy and after 3, 6, 9
and 12 months of therapy. R0.2, treatment with agalsidase alfa at 0.2 mg/kg; F0.2,
treatment with agalsidase beta at 0.2 mg/kg; F1.0, treatment with agalsidase beta at
1.0 mg/kg. Data are presented as mean (and sd) values at the indicated time points for
each group.In female patients, plasma lysoGb3 levels are much lower than in
male patients. A direct comparison of the effect of different treatments
on plasma lysoGb3 concentration was hampered by the relatively
large variability in its concentration in the investigated females prior
to treatment. However, it is noteworthy that in all heterozygotes, with
each of the treatment regimen, a reduction in plasma lysoGb3 level or
at least stabilization at low level was observed. None of the female
patients developed anti-(α-Gal A) antibodies.
The high plasma concentration of lysoGb3 is characteristic for
patients with classical manifestations of Fabry disease. A role for
lysoGb3 in pathogenesis of Fabry disease, as suggested for deacylated
galactosylceramide in Krabbe disease [42–44], is presently under
investigation. Of note, at concentrations occurring in plasma of
hemizygotes, lysoGb3 has been found to promote smooth muscle
cell proliferation [28]. In addition, lysoGb3 has been reported to
stimulate cultured human podocytes to express TGF-β1, extracellular
matrix proteins (ﬁbronectin and type IV collagen) and the macro-
phage inhibitory factor receptor CD74 [45]. These factors have been
implicated in glomerular injury in diabetic nephropathy. Recent data
suggest that high plasma lysoGb3 correlates with increased risk for
cerebrovascular disease in Fabrymales and LVH in Fabry females. Life-
time exposure to lysoGb3, assessed as plasma lipid concentrations
multiplied by age, was found to correlate with disease severity inmale
as well as female patients [41]. These observations suggest, but
certainly do not prove, that lysoGb3 plays a direct role in the
pathogenesis of Fabry disease. Of note, only partial corrections in
plasma lysoGb3 concentrations of male patients receiving ERT were
observed. Apparently, even high dose ERT is insufﬁcient to completely
correct the plasma lysoGb3 abnormality. Thus, it might be possible
that ERT of male Fabry patients results in an ameliorated progression
of disease and not a complete halt or reversal of diseasemanifestation.
We noted no correlation of plasma lysoGb3 content of male Fabry
patients with disease manifestation prior to, or after one year of
therapy. Among female Fabry patients, the combined disease severity
score (Mainz severity scoring index (MSSI) [46]) showed no
signiﬁcant correlation with plasma lysoGb3 levels prior to treatment
(Spearman ρ 0.4421; P=0.099). Changes in plasma lysoGb3 within
one year of ERTwere no obvious predictor for changes in some clinical
parameter.
At present plasma lysoGb3 does not qualify as surrogate marker of
Fabry disease. Long-term follow-up of Fabry patients receiving ERT
has to reveal whether plasma lysoGb3 levels correlate with mean-
ingful clinical outcomes such as progression of cardiac, renal orTable 3
Effect of different treatment regimens on plasma levels of lysoGb3 and Gb3 in female
Fabry patients. The data reﬂect absolute numbers (median and range) and sample size
(n). R0.2, treatment with agalsidase alfa at 0.2 mg/kg; F0.2, treatment with agalsidase
beta at 0.2 mg/kg; F1.0, treatment with agalsidase beta at 1.0 mg/kg. Normal values for
lysoGb3 b3 nM, normal values for Gb3 b3.18 μM.
Females LysoGb3 (nM)
t=0 t=12
Median Range n Median Range n
Total 14 (0–143) 21 8 (0–35) 21
R0.2 23 (12–26) 7 13 (6–19) 7
F0.2 11 (7–29) 5 8 (6–30) 5
F1.0 8 (0–143) 9 5 (0–35) 9
Females Gb3 (μM)
t=0 t=12
Median Range n Median Range n
Total 2.61 (0.77–6.76) 21 2.11 (0.79–3.65) 20
R0.2 2.82 (2.45–3.28) 7 2.44 (2.02–3.60) 7
F0.2 2.34 (0.77–4.18) 5 2.48 (1.40–3.01) 5
F1.0 2.53 (1.20–6.76) 9 1.76 (0.79–3.65) 8
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analyze whether a poor response in plasma lysoGb3 following ERT is
associated with a poor clinical response. Since it has become clear that
advanced disease cannot be reversed by ERT, correction of lysoGb3 is
presumably of little value in this group. However, when early
treatment has been installed, measurement of plasma lysoGb3
concentration may prove to be a valuable tool in clinical management
of Fabry patients before irreversible damage has occurred.
In conclusion, our investigation has rendered a valuable new
insight. ERT of patients with classical manifestations of Fabry dis-
ease with recombinant α-Gal A preparations results in correction of
plasma lysoGb3. This ﬁnding further substantiates that ERT is capa-
ble of correcting a characteristic biochemical abnormality in Fabry
patients.
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